Clinical trial · no report yet · Phase 1
MPN
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
- NCT06291987 ↗
- Recruiting
- University of Chicago
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 49 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b Trial of Ivosidenib Combined With Ruxolitinib in IDH1-Mutated Advanced-Phase MPNs
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Myeloproliferative Neoplasms
- Interventions
- Ivosidenib; Ruxolitinib
- Arms
- Dose Level -1 · Experimental
- Dose Level 1 · Experimental
- Dose Level 2 · Experimental
- Enrollment
- 18 (estimated)
- Primary outcomes
- Maximum tolerated dose
- Sponsor
- University of Chicago
- Start
- Sep 19, 2024
- Primary completion
- May 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06291987 · updated Sep 1, 2026